Survivin downregulation by siRNA/cationic liposome complex radiosensitises human hepatoma cells invitro and invivo

International Journal of Radiation Biology

Volumn 86, Issue 6, 2010, Pages 445-457

  Yang, Wei ^a   Sun, Ting ^b   Cao, Jianping ^a   Liu, Fenju ^a  

^a Department of Radiobiology   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Cationic liposome; Human hepatoma; Radiotherapy; SiRNA; Survivin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BIOLOGICAL MARKER; LIPOSOME; SHORT HAIRPIN RNA; SURVIVIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMING UNIT; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOSENSITIVITY; RADIOSENSITIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL TIME; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LIPOSOMES; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION TOLERANCE; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; X-RAYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 77952511905     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553001003668006     Document Type: Article

References (37)

1. Aagaard L, Rossi JJ. 2007. RNAi therapeutics: principles, prospects and challenges. Advanced Drug Delivery Reviews 5:75-86.
2. Altieri DC. 2003. Survivin and apoptosis control. Advances in Cancer Research 8:31-52.
3. Altieri DC. 2008. Survivin, cancer networks and pathway-directed drug discovery. Nature Reviews. Cancer 81:61-70.
4. Altieri DC. 2003. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22:8581-8589.
5. Ambrosini G, Adida C, Altieri DC. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine 3:917-921.
6. Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A, Watanabe N. 2002. A role for survivin in radioresistance of pancreatic cancer cells. Japanese Journal of Cancer Research 9:1057-1062.
7. Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC. 2004. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. The Journal of Biological Chemistry 279:2077-2084.
8. Cao C, Mu Y, Hallahan DE, Lu B. 2004. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23:7047-7052. (Pubitemid 39319166)
9. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. 2003. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. Journal of Cell Science 116:2987-2998.
10. Chien PY, Wang J, Carbonaro D, Lei S, Miller B, Sheikh S, Ali SM, Ahmad MU, Ahmad I. 2005. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Therapy 12:321-328.
11. Christopher DM, Christopher PN, Giuseppe G, Margaret MM, Ashley RD, David PB. 2007. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. European Journal of Cancer 43:979-992.
12. Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL, Osinaga E, Rabinovich GA, Rivarola VA. 2008. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase independent pathway. Journal of Cellular Biochemistry 10:381-390.
13. Ding SG, Li CG, Lin SR, Yang Y, Liu DH, Han YJ, Zhang Y, Li LN, Zhou LY, Kumar S. 2006. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Human Pathology 37:861-866.
14. Fisker N, Westergaard M, Hansen HF, Hansen JB. 2007. Survivin mRNA antagonists using locked nucleic Acid, potential for molecular cancer therapy. Nucleosides, Nucleotides & Nucleic Acids 26:1427-1430.
15. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. 2003. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155-1159.
16. Kappler M, Taubert H, Bartel F, Blümke K, Panian M, Schmidt H, Dunst J, Bache M. 2005. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncology Reports 13:167-172.
17. Li FZ. 2003. Survivin study: what is the next wave? Journal of Cellular Physiology 19:8-29.
18. Liu H, Guo S, Roll R, Li J, Diao Z, Shao N, Riley MR, Cole AM, Robinson JP, Snead NM, Shen G, Guo P. 2007. Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biology & Therapy 6:697-704.
19. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF. 2001. International trends and patterns of primary liver cancer. International Journal of Cancer 94:290-296.
20. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. 2008. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29:3477-3496.
21. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M, Sasamata M. 2007. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone refractory prostate tumor xenografts. Cancer Research 67:8014-8021.
22. Peng XC, Yang L, Yang LP, Mao YQ, Yang HS, Liu JY, Zhang DM, Chen LJ, Wei YQ. 2008. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34->Ala mutant. Journal of Experimental & Clinical Cancer Research 27:46.
23. Pennati M, Binda M, Colella G, Zoppe M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N. 2004. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23:386-394.
24. Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, Chang EH. 2006. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Human Gene Therapy 17:117-124.
25. Poon RT, Fan ST, Yu WC, Lam BK, Chan FY, Wong J. 2001. A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Archives of Surgery 136:693-699.
26. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F. 2003. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. International Journal of Radiation Oncology, Biology, Physics 55:1341-1347.
27. Roedel F, Frey B, Leitmann W, Capalbo G, Weiss C, Roedel C. 2008. Survivin antisense oligonucleotides effectively radiosensitise colorectal cancer cells in both tissue culture and murine xenograft models. International Journal of Radiation Oncology, Biology, Physics 71:247-255.
28. Roedel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R. 2005. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Research 65:4881-4887.
29. Ryan BM, O'Donovan N, Duffy MJ. 2009. Survivin: a new target for anti-cancer therapy. Cancer Treatment Reviews 35:553-562.
30. Sah NK, Munshi A, Hobbs M, Carter BZ, Andreeff M, Meyn RE. 2006. Effect of down-regulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. International Journal of Radiation Oncology, Biology, Physics 66:852-859.
31. Song H, Xin XY, Xiao F, Wang DT, Yue QH, Han X. 2008. Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. European Journal of Obstetrics, Gynecology, and Reproductive Biology 13:83-89.
32. Talbot D, Davies J, Callies S. 2008. First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit surviving. Journal of Clinical Oncology 26: Abst No. 3518.
33. Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T, Sasaki K, Mizushima Y, Minamida H, Kimura H, Akiyama M, Hirohashi Y, Asanuma H, Tamura Y, Shimozawa K, Sato N, Hirata K. 2004. Phase I clinical study of anti-apoptosis protein, survivinderived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. Journal of Translational Medicine 2:19.
34. Tsuruma T, Iwayama Y, Ohmura T, Katsuramaki T, Hata F, Furuhata T, Yamaguchi K, Kimura Y, Torigoe T, Toyota N, Yagihashi A, Hirohashi Y, Asanuma H, Shimozawa K, Okazaki M, Mizushima Y, Nomura N, Sato N, Hirata K. 2008. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. Journal of Translational Medicine 6:24.
35. Wang R, Li B, Wang X, Lin F, Gao P, Cheng SY, Zhang HZ. 2009. Inhibiting XIAP expression by RNAi to inhibit proliferation and enhance radiosensitivity in laryngeal cancer cell line. Auris Nasus Larynx 36:332-339.
36. Yano J, Hirabayashi K, Nakagawa, Yamaguchi T, Nogawa M, Kashimori I, Naito H, Kitagawa H, Ishiyama K, Ohgi T, Irimura T. 2004. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clinical Cancer Research 10:7721-7726.
37. Zhen HN, Li LW, Zhang W, Fei Z, Shi CH, Yang TT, Bai WT, Zhang X. 2007. Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. International Journal of Oncology 31:1111-1117